Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Angle Will Reshape Liquid Diagnostics By Capturing Circulating Tumor Cells

Executive Summary

Following a successful fundraise, Angle is poised to further commercialize its proprietary cell-catching technology for cancer diagnosis

You may also be interested in...



Minute Insight: Hedera DX Completes €14m Raise To Fund ML-Backed Liquid Biopsy Tech

Hedera DX’s liquid biopsy test uses machine learning to recommend drugs to patients based on a tumor’s circulating DNA profile.

Owlstone Medical Secures Funding To Develop Its Breath Biopsy Technology

The oversubscribed $58m funding round will enable the company to further work on its first-in-class breath biopsy technology, which aims to provide a cheap and convenient screening tool for several diseases.

Angle Files De Novo Submission For Parsortix System In Breast Cancer

The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT144198

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel